Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader ...
A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas ...
There is no Morningstar’s Analysis data available. We sell different types of products and services to both investment professionals and individual investors. These products and services are ...
Hosted on MSN1mon
HC Wainwright & Co. Initiates Coverage of Zenas BioPharma (ZBIO) with Buy RecommendationAnalyst Price Forecast Suggests 328.89% Upside As of December 3, 2024, the average one-year price target for Zenas BioPharma is $37.48/share. The forecasts range from a low of $27.27 to a high of ...
Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 million to ...
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback